Cargando…

Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus

BACKGROUND: The inhibitory CTLA-4 molecule is a crucial regulator of immune responses and a target for therapeutic intervention in both autoimmunity and cancer. In particular, CTLA-4 is important in controlling antigen-specific immunity, including responses to autoantigens associated with autoimmune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dahal, Lekh N., Basu, Neil, Youssef, Hazem, Khanolkar, Rahul C., Barker, Robert N., Erwig, Lars P., Ward, Frank J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973056/ https://www.ncbi.nlm.nih.gov/pubmed/27487771 http://dx.doi.org/10.1186/s13075-016-1075-1

Ejemplares similares

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

CTLA-4 Gene Polymorphism and the Risk of Systemic Lupus Erythematosus in the Chinese Population
por: Taha Khalaf, Ahmad, et al.
Publicado: (2011)

TGF-β2 mediated secretion of sCTLA-4 from regulatory T cells
por: Khanolkar, R, et al.
Publicado: (2015)

Immunoglobulin E plays an immunoregulatory role in lupus
por: Dema, Barbara, et al.
Publicado: (2014)

Elevated levels of soluble intercellular adhesion molecule -1 in systemic lupus erythematosus
por: Kljukvina, N, et al.
Publicado: (2001)

Polymorphic Sites at the Immunoregulatory CTLA-4 Gene Are Associated with Chronic Chagas Disease and Its Clinical Manifestations
por: Dias, Fabrício C., et al.
Publicado: (2013)

On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies
por: Ward, Frank J., et al.
Publicado: (2018)

Association of the CTLA-4 1722TC polymorphism and systemic lupus erythematosus: a systematic review and meta analysis
por: Shojaa, Mahdieh, et al.
Publicado: (2014)

Analysis of CD95 and CCR7 expression on circulating CD4(+) lymphocytes revealed disparate immunoregulatory potentials in systemic lupus erythematosus
por: Aldahlawi, Alia M., et al.
Publicado: (2016)

Increased concentration of serum soluble LAG3 in systemic lupus erythematosus
por: Yu, Seri, et al.
Publicado: (2012)

IL-1 family cytokines and soluble receptors in systemic lupus erythematosus
por: Italiani, Paola, et al.
Publicado: (2018)

Disseminated Lupus Erythematosus
por: Konar, N. R., et al.
Publicado: (1950)

Imbalanced expression of functional surface molecules in regulatory and effector T cells in systemic lupus erythematosus
por: Mesquita Júnior, D., et al.
Publicado: (2014)

Decreased serum level of soluble-leptin-receptor in patients with systemic lupus erythematosus
por: Bagheri, K, et al.
Publicado: (2012)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Macrophages as host, effector and immunoregulatory cells in leishmaniasis: Impact of tissue micro-environment and metabolism
por: Bogdan, Christian
Publicado: (2020)

Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review
por: Wells, Georgia, et al.
Publicado: (2021)

Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics
por: Smith, F. Donelson, et al.
Publicado: (2023)

Lupus Erythematosus
por: Gardiner, Frederick
Publicado: (1923)

Lupus Erythematosus
por: Ravogli, A.
Publicado: (1887)

Lupus nephropathy as the initial manifestation of systemic lupus erythematosus.
por: Lynn, R. I., et al.
Publicado: (1980)

Linear cutaneous lupus erythematosus/discoid lupus erythematosus in an adult
por: Mao, Qiu-Xia, et al.
Publicado: (2017)

Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients
por: Gómez-Bernal, Fuensanta, et al.
Publicado: (2022)

Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity
por: Ceccarelli, Fulvia, et al.
Publicado: (2023)

Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double‐blind Phase Ib study
por: Walker, Alex, et al.
Publicado: (2020)

Investigation of Soluble and Transmembrane CTLA-4 Isoforms in Serum and Microvesicles
por: Esposito, Laura, et al.
Publicado: (2014)

Melatonin exerts immunoregulatory effects by balancing peripheral effector and regulatory T helper cells in myasthenia gravis
por: Chang, Ting, et al.
Publicado: (2020)

Genetic epidemiology: Systemic lupus erythematosus
por: Ahmad, Yasmeen A, et al.
Publicado: (2001)

Neuropsychiatric Systemic Lupus Erythematosus: A Diagnostic Conundrum
por: Joseph, Vivek, et al.
Publicado: (2016)

The Possible Clinical Significance of a Decreased Serum Level of Soluble PD-L1 in Discoid Lupus Erythematosus, but Not in Subacute Cutaneous Lupus Erythematosus—A Pilot Study
por: Király, Zsófia, et al.
Publicado: (2023)

Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept
por: Tarazi, Meera, et al.
Publicado: (2018)

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
por: Arce Vargas, Frederick, et al.
Publicado: (2018)

Systemic lupus erythematosus presenting as lupus erythematosus tumidus and lupus nephritis: a case report
por: Hajji, Meriam, et al.
Publicado: (2023)

Immunoregulatory potential of mesenchymal stem cells following activation by macrophage-derived soluble factors
por: Saldaña, Laura, et al.
Publicado: (2019)

Patterns and influence of familial autoimmunity in pediatric systemic lupus erythematosus
por: Walters, Heather M, et al.
Publicado: (2012)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

Interferon Alpha in Systemic Lupus Erythematosus
por: Niewold, Timothy B., et al.
Publicado: (2010)

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
por: Zhang, Jingyu, et al.
Publicado: (2017)

The Role of NETosis in Systemic Lupus Erythematosus
por: Salemme, Ryan, et al.
Publicado: (2019)

Systemic lupus erythematosus.
por: Richardson, J.
Publicado: (1969)

Cannot write session to /tmp/vufind_sessions/sess_oaeprkr027ec4ebuu4bhvrno2p